old.iss.itold.iss.it/binary/publ/cont/Pag._307_311_Vol._33_N.3_1997_Annali.pdf · risk of...

5

Transcript of old.iss.itold.iss.it/binary/publ/cont/Pag._307_311_Vol._33_N.3_1997_Annali.pdf · risk of...

Page 1: old.iss.itold.iss.it/binary/publ/cont/Pag._307_311_Vol._33_N.3_1997_Annali.pdf · risk of malformations and maternal use of sulphonylureas drugs during the first 8 weeks of gestation.
Page 2: old.iss.itold.iss.it/binary/publ/cont/Pag._307_311_Vol._33_N.3_1997_Annali.pdf · risk of malformations and maternal use of sulphonylureas drugs during the first 8 weeks of gestation.
Page 3: old.iss.itold.iss.it/binary/publ/cont/Pag._307_311_Vol._33_N.3_1997_Annali.pdf · risk of malformations and maternal use of sulphonylureas drugs during the first 8 weeks of gestation.
Page 4: old.iss.itold.iss.it/binary/publ/cont/Pag._307_311_Vol._33_N.3_1997_Annali.pdf · risk of malformations and maternal use of sulphonylureas drugs during the first 8 weeks of gestation.
Page 5: old.iss.itold.iss.it/binary/publ/cont/Pag._307_311_Vol._33_N.3_1997_Annali.pdf · risk of malformations and maternal use of sulphonylureas drugs during the first 8 weeks of gestation.